A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom® formulations in Cameroonian women

Contraception

Volumn 81, Issue 1, 2010, Pages 79-85

  Mbopi Keou, Francois Xavier ^a   Trottier, Sylvie ^b   Omar, Rabeea F ^b   Nkele, Ngoh N ^c   Fokoua, Séraphin ^c   Mbu, Enow R ^d   Domingo, Marc Christian ^b   Giguère, Jean Francois ^b   Piret, Jocelyne ^b   Mwatha, Anthony ^e   Mâsse, Benoît ^e   Bergeron, Michel G ^b  

^a MINISTRY OF PUBLIC HEALTH   (Cameroon)

^b LAVAL UNIVERSITY   (Canada)

^c Obstetrics and Pediatrics Hospital   (Cameroon)

^d YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cameroon; Double blind; HIV STI prevention; Invisible Condom ; Placebo controlled trial; Randomized; Vaginal microbicides; Women

Indexed keywords

DODECYL SULFATE SODIUM PLUS POLYMER; HYDROGEN PEROXIDE; INVISIBLE CONDOM; MICROBICIDE; PLACEBO; POLYMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAMEROON; CANDIDIASIS; CLINICAL TRIAL; COLPOSCOPY; CONDOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTOBACILLUS; LEUKORRHEA; NORMAL HUMAN; PELVIS PAIN SYNDROME; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAFETY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINITIS; WOMEN'S HEALTH;

EID: 71449121884     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.07.002     Document Type: Article

References (35)

1. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 (2007) 787-797
2. Feldblum P.J., Adeiga A., Bakare R., et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 3 (2008) e1474
3. Skoler-Karpoff S., Ramjee G., Ahmed K., et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1977-1987
4. Van Damme L., Govinden R., Mirembe F.M., et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359 (2008) 463-472
5. Editorial. Newer approaches to HIV prevention. Lancet 369 (2007) 615
6. Johnston R. Microbicides 2002: an update. AIDS Patient Care STDS 16 (2002) 419-430
7. Bentley M.E., Fullem A.M., Tolley E.E., et al. Acceptability of a microbicide among women and their partners in a 4-country Phase I trial. Am J Public Health 94 (2004) 1159-1164
8. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2008 report on the global AIDS epidemic. Accessed on 1st of December 2008 at. http://data.unaids.org/en/knowledgecentre/HIVdata/epidemiology/epidemiol ogyslidesauto.asp
9. WHO. The world health report 2002. Reducing risks, promoting healthy life (2002). www.who.int/whr/2002/en/ [Accessed October 2004]
10. WHO. Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. Reference number: WHO/HIV_AIDS/2001.02 (2001). http://www.who.int/hiv/pub/sti/pub7/en/index.html
11. Mbopi-Keou F.X., Ongolo-Zogo P., Angwafo III F., Ndumbe P.M., and Belec L. High impact of mobile units for mass HIV testing in Africa. AIDS 21 (2007) 1994-1996
12. Bestman-Smith J., Piret J., Desormeaux A., Tremblay M.J., Omar R.F., and Bergeron M.G. Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment. Antimicrob Agents Chemother 45 (2001) 2229-2237
13. Piret J., Gagne N., Perron S., et al. Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and Herpes simplex virus type 2. Sex Transm Dis 28 (2001) 484-491
14. Piret J., Roy S., Gagnon M., et al. Comparative study of mechanisms of Herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. Antimicrob Agents Chemother 46 (2002) 2933-2942
15. Roy S., Gourde P., Piret J., et al. Thermoreversible gel formulations containing sodium lauryl sulfate or n-lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother 45 (2001) 1671-1681
16. Piret J., Laforest G., Bussieres M., and Bergeron M.G. Subchronic (26- and 52-week) toxicity and irritation studies of a novel microbicidal gel formulation containing sodium lauryl sulfate in animal models. J Appl Toxicol 28 (2008) 164-174
17. Howett M.K., Neely E.B., Christensen N.D., et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother 43 (1999) 314-321
18. Haineault C., Gourde P., Perron S., et al. Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device. Biol Reprod 69 (2003) 687-694
19. Trottier S., Omar R.F., Desormeaux A., et al. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Contraception 76 (2007) 117-125
20. Omar R.F., Trottier S., Brousseau G., Lamarre A., Alexandre G., and Bergeron M.G. Distribution of a vaginal gel (Invisible Condom) before, during and after simulated sexual intercourse and its persistence when delivered by two different vaginal applicators: a magnetic resonance imaging study. Contraception 77 (2008) 447-455
21. Mbopi-Keou F.-X., Trottier S., Omar R.F., et al. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom® formulations in women from Cameroon. Contraception 80 (2009) 484-492
22. Schwartz J.L., Ballagh S.A., Kwok C., et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 75 (2007) 136-141
23. Tien D., Schnaare R.L., Kang F., et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21 (2005) 845-853
24. Nugent R.P., Krohn M.A., and Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 29 (1991) 297-301
25. World Health Organization (WHO)/Contraceptive Research and Development Program (CONRAD). Manual for the standarisation of colposcopy for the evaluation of vaginal products, Update 2004.CONRAD/2004.1/WHO/RHR/04.02.
26. McGroarty J.A., Tomeczek L., Pond D.G., Reid G., and Bruce A.W. Hydrogen peroxide production by Lactobacillus species: correlation with susceptibility to the spermicidal compound nonoxynol-9. J Infect Dis 165 (1992) 1142-1144
27. Richardson B.A., Martin Jr. H.L., Stevens C.E., et al. Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis 178 (1998) 441-445
28. Amsel R., Totten P.A., Spiegel C.A., Chen K.C., Eschenbach D., and Holmes K.K. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74 (1983) 14-22
29. Tabbara S., Saleh A.D., Andersen W.A., Barber S.R., Taylor P.T., and Crum C.P. The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic, and viral correlates. Obstet Gynecol 79 (1992) 338-346
30. Joshi S., Dutta S., Bell B., et al. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned. AIDS Res Hum Retroviruses 22 (2006) 294-296
31. Kilmarx P.H., van de Wijgert J.H., Chaikummao S., et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a Phase II clinical trial. J Acquir Immune Defic Syndr 43 (2006) 327-334
32. Mayer K.H., Maslankowski L.A., Gai F., et al. Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20 (2006) 543-551
33. Mayer K.H., Peipert J., Fleming T., et al. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 32 (2001) 476-482
34. Gupta K.M., Barnes S.R., Tangaro R.A., et al. Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci 96 (2007) 670-681
35. Juhasz J., Pimienta C., and Lenaerts V. Adhesion of poloxamer 407 formulations on dog ileal segments in vitro. Eur J Pharm Biopharm 37 (1991) 262-265